US › Healthcare

Entera Bio Ltd (ENTX)

US · Healthcare · Biotechnology

$3.03+2.36%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.3M

EPS

$-0.14

EPS estimate

$-0.08

EPS came in at -0.14 against a street estimate of -0.08 — a miss of 75.0%.

Key statistics

Market cap

$495.2M

Forward P/E

0.0

P/B

67.20

Book value

$0.15

EPS (TTM)

$-0.35

52-week high

$4.20

52-week low

$0.91

50-day MA

$2.66

200-day MA

$1.76

Beta

1.39

Analyst view

Analysts rate Entera Bio Ltd a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $9.00.

Shareholding

Insiders

6.85%

Institutions

34.11%

Largest institutional holders

Fund	Stake
Knoll Capital Management LP	3.38%
Renaissance Technologies Corp	0.27%
Parkman Healthcare Partners LLC	0.16%
Citadel Advisors Llc	0.14%
Seven Fleet Capital Management LP	0.12%
Marshall Wace Asset Management Ltd	0.11%
Northern Trust Corp	0.08%
XTX Topco Ltd	0.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Entera Bio Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.